enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial
ACCESSWIRE•02/10/2026•08:44 ET
1
Key Highlights
- ➤FDA IDE approval enables TAVVE pivotal trial for enVVe System (NVNO)
- ➤TAVVE study enrollment expected to begin in Q4 of 2026
- ➤enVVe System to be presented at The VEINS 2026 Innovation Summit
- ➤enVVe System is a first-in-class, non-surgical replacement venous valve
Expert Statements
Rob Berman, Chief Executive Officer of enVVeno Medical
“The VEINS 2026 Summit is an important opportunity to introduce the enVVe(®) System to the world's leading venous specialists who treat patients with severe deep venous disease on a daily basis”
Rob Berman, Chief Executive Officer of enVVeno Medical
“For decades, physicians have lacked the ability to replace damaged valves which are the most frequent cause of severe deep venous insufficiency.”
IRVINE, CA / ACCESS Newswire / October 2, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that the Company will present its investigational enVVe(®) System at The VEINS 2026 in Las Vegas, Nevada.
The presentation will take place on Sunday, October 4, 2026 at the Blue Sky Breakfast consisting of a gathering of specialists focused on advances in venous and vascular disease. The presentation will be followed by panel discussion and Q&A session.
Get started
Create a free account to read the full story.